FDAsafety guidance72% confidence
Drug Trials Snapshots: VOYXACT
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Suvorexant.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Psychiatry · Sleep Disorders
- Sub-indication
- General
Related signal: University of Maryland Evaluates Suvorexant for Reducing Drug Demand